| 000 | 01791 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515013552.0 | ||
| 264 | 0 | _c20060331 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a1352-0504 | ||
| 024 | 7 |
_a10.1111/j.1365-2893.2005.00694.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlric, L | |
| 245 | 0 | 0 |
_aPilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _cFeb 2006 |
||
| 300 |
_a139-44 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 | _aSpecies Specificity |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aThebault, S | |
| 700 | 1 | _aPeron, J-M | |
| 700 | 1 | _aBalard, P | |
| 700 | 1 | _aMetivier, S | |
| 700 | 1 | _aPipy, B | |
| 700 | 1 | _aIzopet, J | |
| 700 | 1 | _aVinel, J-P | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 13 _gno. 2 _gp. 139-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2893.2005.00694.x _zAvailable from publisher's website |
| 999 |
_c16050781 _d16050781 |
||